Testing the Safety and Efficacy of the Combination of the Antibody Pembrolizumab and Entinostat in Patients With Myelodysplastic Syndrome Who Are Not Responding to Hypomethylating Agents

MedStar Georgetown University Hospital, Washington D.C.

UNC Lineberger Comprehensive Cancer Center, Chapel Hill

Duke University Medical Center, Durham

University of Kentucky/Markey Cancer Center, Lexington

UC Comprehensive Cancer Center at Silver Cross, New Lenox

University of Chicago Medicine-Orland Park, Orland Park

Northwestern University, Chicago

University of Chicago Comprehensive Cancer Center, Chicago

University of Kansas Cancer Center, Kansas City

University of Kansas Clinical Research Center, Fairway

University of Kansas Hospital-Westwood Cancer Center, Westwood

Nebraska Medicine-Village Pointe, Omaha

University of Nebraska Medical Center, Omaha

UT Southwestern/Simmons Cancer Center-Dallas, Dallas

Huntsman Cancer Institute/University of Utah, Salt Lake City

Smilow Cancer Center/Yale-New Haven Hospital, New Haven

Yale University, New Haven

Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center, Lebanon

Rutgers Cancer Institute of New Jersey, New Brunswick